GlassScriptPhysician profile
Vanessa R Mcclellan
NPI 1407177579
$16,006.73
in general payments reported to CMS, 2019-2025
28 companies · $59.56 in 2025
The $59.56 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,974 · 2020: $4,078 · 2021: $3,819 · 2022: $3,242 · 2023: $512 · 2024: $322 · 2025: $59.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $13,440.00 | 2019-2022 | |
| Abbvie INC. | $491.83 | 2021-2024 | |
| Allergan, INC. | $369.88 | 2019-2020 | |
| Glaxosmithkline, LLC. | $217.50 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $207.01 | 2019-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $203.74 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $169.48 | 2019-2024 | Mounjaro |
| Pfizer INC. | $167.57 | 2019-2024 | |
| Astellas Pharma US INC | $165.51 | 2021-2025 | Veozah |
| Boston Scientific Corporation | $131.39 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $75.93 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.22 | 2021 | |
| Merck Sharp & Dohme LLC | $32.81 | 2019-2020 | |
| Novo Nordisk INC | $31.91 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $30.05 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainsway USA INC | $27.45 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.12 | 2021 | |
| Nestle Healthcare Nutrition INC. | $25.58 | 2021 | |
| Dexcom, INC. | $23.74 | 2023 | Dexcom G6 Transmitter |
| Eisai INC. | $15.81 | 2021 | |
| Axsome Therapeutics, INC. | $15.50 | 2025 | Auvelity |
| Seqirus USA INC | $15.10 | 2019 | |
| Amgen INC. | $14.30 | 2025 | Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.79 | 2022 | |
| Organon LLC | $13.29 | 2024 | |
| Radius Health, INC. | $13.22 | 2020 | |
| Sanofi Pasteur INC. | $12.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Mcclellan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.